Contraindications for taking Apremilast

Apremilast(Apremilast) is an oral medication used to treat psoriasis (psoriasis) and psoriatic arthritis (psoriatic arthritis). Although it is widely used in clinical treatment, there are some contraindications that patients using Apremilast should be careful to avoid. Here are some common contraindications:

1. Allergic reaction:

Patients who have an allergy to apremilast or any of its components should avoid use of this medication. Allergic reactions may manifest as rash, itching, hives, difficulty breathing, swelling of the throat, and other symptoms. If a patient develops these symptoms, they should stop using Apremilast immediately and seek medical advice.

2. Severe liver damage:

In patients with severe hepatic impairment, Apremilast may worsen the condition and should be avoided. Severe liver damage may manifest as jaundice, abnormal liver function, abdominal distension, ascites and other symptoms. Before using Apremilast, patients' liver function should be evaluated and use should be avoided in patients with impaired liver function.

3. Severe renal impairment:

Because Apremilast is metabolized and excreted primarily through the kidneys, its use should be avoided in patients with severe renal impairment. Severe kidney damage may cause the drug to accumulate in the body, increasing the risk of side effects. The patient's renal function should be evaluated before useApremilast and should be used with caution in cases of impaired renal function.

4. Pregnancy and lactation:

There are insufficient clinical data to determine the safety of apremilast during pregnancy. Therefore, pregnant women should avoid using Apremilast unless specifically directed by a doctor. In addition, Apremilast may be excreted in breast milk and should be avoided during breastfeeding.

5. Severe cardiovascular disease:

For patients with existing serious cardiovascular diseases, such as heart failure, arrhythmia, etc., the use of Apremilast (apmilast) should be avoided. Apremilast (Apremilast)A risk associated with cardiovascular events has been observed in clinical trials, so the safety in these patients is uncertain.

6. Immunosuppression:

Due to Apremilast's modulating effect on the immune system, there is a risk of immunosuppression. Therefore, patients with immunosuppressive diseases or who are receiving immunosuppressive therapy should avoid the use of Apremilast (apmilast) to avoid an increased risk of infection and other immune-related risks.

7. Under18 years old:

Currently, the safety and effectiveness of apremilast (apmilast) in patients under 18 years have not been established and use in this age group is not recommended.

In summary, Apremilast (Apremilast) is contraindicated in some circumstances, including allergies to drug ingredients, severe liver and kidney function impairment, pregnant and lactating women, severe cardiovascular disease, immunosuppression, and patients under18 years of age. Before using Apremilast , patients should receive adequate physician evaluation and guidance to ensure safe and effective treatment.